Meet the AdvisorsAntibodies for Cancer Therapy:
Exploiting Successful Strategies


Day 1 | Day 2 | Download Stream Brochure 


4:00 - 6:00 pm Main Conference Registration




7:00 am Registration and Morning Coffee



8:30 Chairperson’s Opening Remarks 

Richard Wagner Richard Wagner, Ph.D., Executive Chairman and CSO, X-Body Biosciences, Inc. 



8:40 Antibodies for Cancer: Past, Present and Future

Janice Reichert Janice Reichert, Ph.D., Research Assistant Professor, Tufts Center for the Study of Drug Development, Tufts University School of Medicine 

The majority of development programs for monoclonal antibodies have focused on cancer, resulting in nearly a dozen marketed products and a variety of novel antibody modalities in clinical study. An overview of development and approval trends for novel anti-cancer mAbs, including bispecific antibodies and antibody-drug conjugates, will be discussed. 

9:10 Kymouse Platform to Generate Highly Selective, Potent and Well-Tolerated Human Antibody-Based Biopharmaceuticals 

Allan Bradley Allan Bradley, Ph.D., FRS, Director Emeritus, Wellcome Trust Sanger Institute


9:40 Sphingosine-1-Phosphate Antibodies as Potential Agents in the Treatment of Cancer and Age-Related Macular Degeneration 

Roger Sabbadini Roger A. Sabbadini, Ph.D., Founder, Vice President & CSO, Lpath, Inc.; Professor Emeritus, Biology, San Diego State University 

Bioactive lipids are novel targets for antibody therapeutic drug discovery. The bioactive lipid, Sphingosine-1-Phosphate (S1P), is a pleiotropic extracellular signaling molecule thought to be dysregulated in a variety of disease conditions, including cancer. In this presentation, Dr. Sabbadini will discuss the tumorigenic and angiogenic roles of S1P and the use of the ant-S1P antibody, sonepcizumab, to neutralize dysregulated S1P in cancer patients. S1P as a potential tumor biomarker is also discussed. 

10:10 Grand Opening Coffee Break in the Exhibit Hall with Poster Viewing


Direct Killing of Cancer Cells 

11:05 Chairperson’s Remarks 

Richard Wagner Richard Wagner, Ph.D., Executive Chairman and CSO, X-Body Biosciences, Inc. 





11:10 Overview of the Role of FC-Gamma Receptors and the Roles in Antibody Efficacy

Raphael Clynes Raphael Clynes, M.D., Ph.D., Associate Professor, Pulmonary & Allergy & Critical Care, Columbia University

Antitumor antibodies establish the paradigm that engineered therapeutic antibodies should engage activatory over inhibitory Fc receptors. I will discuss my research on the immunoregulation of dendritic cells in immunity and inflammation demonstrating that antitumor antibodies drive T cell responses that are relevant to efficacy.


11:40 Antibody scFv-Based Chimeric Immune Receptors for Optimized Adoptive T Cell Therapy of Cancer

Daniel Powell Daniel J. Powell Jr., Ph.D., Research Assistant Professor, Pathology & Lab Medicine; Deputy Director, Cell & Vaccine Production Facility, University of Pennsylvania

Chimeric immune receptors (CIRs) couple the high affinity binding of antibody scFv with the intracellular signaling domains of the T cell receptor and costimulatory molecules for the specific retargeting of T lymphocytes to tumor antigens. Accordingly, CIR expressing T cells mediate the specific killing of cancers cells in vitro, and deliver potent antitumor activity in vivo.


12:10 pm Sponsored Presentations (Opportunities Available)

     Sponsored by
12:40 Luncheon Presentation 
Kinetics on Cells-Bridging the Gap Between Traditional Biosensor and Cell Based Assay

Teodor Aastrup, Ph.D., CEO, Attana ABTwo typical examples where the Attana Cell 200 proved to be beneficial as the first biosensor in the world that measures molecular interactions label free directly on cell surfaces will be presented 

1:10 Luncheon Presentation (Sponsorship Opportunity Available) or Lunch on Your Own

1:40 Break



2:00 Chairperson’s Remarks

Horacio Nastri Horacio G. Nastri, Ph.D., Head, Antibody Technologies, EMD Serono Research Center, Inc.


2:05 The Promise and Challenge of Therapeutic Antibodies in Oncology: A Regulatory Perspective

Wendy WeinbergWendy Weinberg, Ph.D., Senior Investigator and Chief, Molecular Oncology, Monoclonal Antibodies, Office of Biotechnology Products, CDER/FDA

Technical advances and increased understanding of molecular targets have made antibody therapeutics among the fastest growing sector of drug development. New strategies in protein design, expression systems, and manufacturing provide unique regulatory challenges to ensure the safety and consistency of these complex products.


2:35 Discovery and Characterization of hMAB Targeting an RTK Implicated in Metastasis by Live Cell Screening and Interrogation of Fully Human Libraries with Deep Sequencing

Yan Chen, Ph.D., Vice President, Antibody Research, X-Body Biosciences, Inc.

We describe a novel platform for rapid generation of hMABs that employs interrogation of fully human libraries by deep sequencing. This human library captures the full naïve antibody repertoire and can be screened for binding to targets on living cells. Sequencing of thousands of hits provide an early read on the function, affinity and specificity of lead candidates. Label-free metastasis assays and 384 well affinity determinations in complex fluids are deployed in the screening process.

3:05 Refreshment Break in the Exhibit Hall with Poster Viewing

3:45 Next-Generation Therapeutic Proteins for the Treatment of Solid Tumors: Pre-Clinical and Interim Phase I Results

Laurent AudolyLaurent Audoly, Ph.D., CSO, Pieris AG

Anticalins have been characterized in multiple pre-clinical disease models to demonstrate their potency, efficacy, and unique differentiating features. The presentation will provide an update on PRS050 (VEGFA) currently being dosed in an open Phase I clinical trial, as well as pre-clinical in vivo proof-of-concept for PRS110 (cMet). Characteristics of drug-like properties and manufacturability line of sight will be emphasized, and bispecific anticalins (Duocalins) will be reviewed.

4:15 Induction of HER-2/Neu-Specific Immunity During Combination Trastuzumab and Chemotherapy 

Keith Knutson Keith Knutson, Ph.D., Associate Professor, Immunology, College of Medicine, Mayo Clinic 

The immunologic efficacy of monoclonal antibody therapy is thought to be passive. Recent translational studies however show that combination chemotherapy and trastuzumab induces HER-2/neu-specific immunity. Importantly, these immune responses are linked to clinical outcomes. The findings suggest that, under the appropriate conditions, monoclonal antibody therapy may act as a vaccine ensuring protection from disease recurrence.



4:45 Problem Solving Breakout Sessions 

Concurrent Problem Solving Breakouts are interactive sessions hosted by a moderator to discuss a topic in depth. They are open to all attendees, sponsors, exhibitors, and speakers and provide a forum for discussing key issues and meeting potential partners. Please pick a topic of your choice and join in. 

TABLE 21: Improving Anti-Cancer Antibodies 

Moderator: Xiaodong Yang, M.D., President & CEO, Apexigen, Inc. 

• What are the key attributes of successful anti-cancer antibodies?
• What are criteria for assessing improved potency and efficacy?
• What can/should be done to increase the probability of success of ‘improved” anti-cancer antibodies?

TABLE 22: Targeting Cancer Stem Cells (CSCs) 

Moderator: John Lewicki, Ph.D., Executive Vice President, Research & Development, OncoMed Pharmaceuticals 

• Technological advances to detect and study CSCs
• Resistance of CSCs to chemotherapy and strategies to overcome it
• Therapeutic approaches to selectively eliminate CSCs in solid tumors
• Approaches for quantifying the effects of therapeutic agents on CSCs

TABLE 23: Engineering Antibody Fragments for Maximum Tumor and Minimum Kidney Uptake 

Moderator: Peter J. Hudson, FTSE, Ph.D., Director, Victorian Cancer Biologics and CSO, Avipep Pty Ltd. 

• Optimising tumor uptake ratios and blood clearance rates
• The impact of tuning Affinity and Avidity to improve %ID/gm
• Strategies to effectively avoid kidney uptake and toxicity
• Highly efficient conjugation methods for ADC (drug loading)

TABLE 24: Redirecting Effector T cells using Cancer-Specific Chimeric Receptors 

Moderator: Zelig Eshhar, Ph.D., Professor, Immunology, The Weizmann Institute of Science 

• Optimization of the structure of the antibody-based chimeric receptor
• Anti-tumor function of redirected T cells
• First steps into the clinic
• Redirection of antigen-specific regulatory T-cells for the suppression of inflammation

5:45- 6:45 Reception in the Exhibit Hall with Poster Viewing

Day 1 | Day 2 | Download Stream Brochure